Robert Ragusa was appointed Director of Alamar Biosciences, Inc., effective September 1, 2026. As of November 6, 2026, Alamar Biosciences, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from September 1, 2026 to November 3, 2026, naming 2 appointments (Form 8-K, September 1, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Alamar Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Alamar Biosciences, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-09-01 to 2026-11-03. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Alamar Biosciences, Inc. files it.
Also on the record for Alamar Biosciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 13, 2026 | Stake report, Schedule 13G, by Yuling Luo | 6.4% of the class | 5%+ stakes | Source |
| August 11, 2026 | Stake report, Schedule 13G, by Qiming Corporate GP VI, Ltd | 10.2% of the class | 5%+ stakes | Source |
| July 7, 2026 | Stake report, Schedule 13D/A, by Sands Capital Life Sciences Pulse Fund II, L.P. | 6.1% of the class | 5%+ stakes | Source |
| July 2, 2026 | Stake report, Schedule 13G, by Daqing Cai | 7.2% of the class | 5%+ stakes | Source |
| April 23, 2026 | Stake report, Schedule 13D, by Illumina Innovation Fund II, L.P. | 9.6% of the class | 5%+ stakes | Source |
| April 23, 2026 | Stake report, Schedule 13D, by Sands Capital Life Sciences Pulse Fund II, L.P. | 6.3% of the class | 5%+ stakes | Source |
| April 17, 2026 | IPO filing, Form 424B4 | $17 a share | IPO filings | Source |
| April 16, 2026 | IPO filing, Form S-1/A | $15 to $17 a share | IPO filings | Source |
| April 13, 2026 | IPO filing, Form S-1/A | $15 to $17 a share | IPO filings | Source |
| March 27, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
Selling to them or working with them? See who runs Alamar Biosciences, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Alamar Biosciences, Inc. and the records around it.
Alamar Biosciences, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Sands Capital Life Sciences Pulse Fund II, L.P. also filed stake reports on 3 other companies: Acrivon Therapeutics, Inc. (Aug 2026), Inhibikase Therapeutics, Inc. (Aug 2026), Beta Bionics, Inc. (Aug 2025)
Watch Alamar Biosciences, Inc.
Get an email when Alamar Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Alamar Biosciences, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Alamar Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Alamar Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-03 | Reported | not named in the filing | 8-K, 2026-11-03 | ||
| 2026-09-01 | In | Director | 2026-09-01 | 8-K, 2026-09-01 | |
| 2026-09-01 | In | 8-K, 2026-09-01 |
Who leads Alamar Biosciences, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Robert Ragusa, appointed, effective 2026-09-01 (filed 2026-09-01).
New leaders reset buying decisions — get the Full Report on Alamar Biosciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Alamar Biosciences, Inc., with the record behind each one.
Find candidates like Director at Alamar Biosciences, Inc.Every change, in the filing's words
Reported
After more than five years of exemplary service, on October 30, 2026, Timothy "Tod" White informed the Company that he will retire from his current position as President of the Company, effective as of December 31, 2026.
- Mr. White has agreed to remain as a consultant to the Company from January 1, 2027 through June 30, 2027 to ensure an orderly transition and continuity of operations.
- Yuling Luo, Ph.D., Founder, Chief Executive Officer, and Chair of the Company said, "Tod has been an outstanding partner and leader during a pivotal period for Alamar." Dr. Luo continued, "He helped build the foundation that is driving our growth today, managed multiple rounds of fundraising, and leaves the company well-positioned for its next phase.
- On behalf of our board and the entire team, I thank Tod for his many contributions and wish him the very best in his retirement."
Appointed: Robert Ragusa, Director, effective 2026-09-01
On August 28, 2026, the board of directors (the "Board") of Alamar Biosciences, Inc. (the "Company") appointed Robert Ragusa to the Board, effective as of September 1, 2026.
Appointed: Robert Ragusa
Mr. Ragusa will serve as a Class I Director, with an initial term expiring at the Company's 2027 Annual Meeting of Stockholders.
- Mr. Ragusa was also appointed to the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee of the Board.
- Mr. Ragusa will be compensated as a member of the Board under the terms of the Company's Non-Employee Director Compensation Policy substantially as described in the Company's final prospectus filed with the U.S. Securities and Exchange Commission on April 17, 2026.
- Mr. Ragusa will enter into the Company's standard form of indemnification agreement.
Tools for this story
Each opens in a new tab, filled in for Alamar Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.